Navigation Links
Reportlinker Adds Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin
Date:2/17/2011

NEW YORK, Feb. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

http://www.reportlinker.com/p0397056/Antifungals-Market-to-2016---Promising-Antifungals-in-Pipeline-Includes-Novel-Azoles-Polyenes-and-Echinocandin.html

Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

Summary

GBI Research, a leading business intelligence provider, has released its latest research "Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin", which provides insights into antifungals sales and price forecasts until 2016. The report examines global treatment usage patterns of antifungals therapies. The geographical distribution of antifungals therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report includes insights into the antifungals R&D pipeline and potential future blockbusters up to 2016. The report provides an in-depth analysis of the top three antifungals therapeutic indications, which are aspergillosis, dermatophytosis and candidiasis. It also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report explores the competitive landscape including top companies benchmarking, and the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies are also presented. In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Research's team of experts. GBI Research's analysis showed that the global antifungals market was estimated at $7.4 billion in 2009, with a year-on-year growth rate of 2.3% between 2001 and 2009. The antifungals market is dominated by target therapeutics, which is more efficient and safe when compared to other conventional therapies. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 1.9% between 2009 and 2016 to record a sales value of $8.4 billion. The patent expiry of the major drugs has also paved the way for the entry of generics.

Scope

The scope of this report includes -

- Annualized market data for the antifungals market from 2001 to 2009, with forecasts to 2016.

- Market analysis for the three major indications in the global antifungals market which includes Aspergillosis, Dermatophytosis and Candidiasis.

- Data and analysis on the antifungals market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- The competitive landscape of the global antifungals market including SWOT analysis

- Key M&A activities and licensing agreements that took place in 2008 and 2009 in the antifungals market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious..

To order this report:

: Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... ... an inspirational interview of two ostomy patients, standing as living proof that attitude ... suffer from digestive diseases and issues that spike around the holidays. This campaign ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):